Oncoheroes Biosciences Inc. (“Oncoheroes”), a biotech focused on advancing new therapies for childhood cancer and member  of CataloniaBio & HealthTech, has out-licensed worldwide the adult rights to Notable Labs, Inc. (“Notable”), a clinical-stage predictive precision medicine company. Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer. Notable will have exclusive rights to develop and commercialize volasertib in adult cancer indications. Financial details of this deal are not disclosed.

Volsertib is a medicine designed by Boehringer Ingelheim for acute myeloid leukemia, until the company decided to leave its development for strategic reasons. In 2019, Oncoheroes obtained the worldwide and exclusive license for the drug with the aim of continuing the clinical development for young oncology patients.

“In-licensing clinical-stage therapies that pass our platform’s rigorous demands like volasertib represents an exciting milestone towards fulfilling Notable’s mission to deliver life-changing therapies precisely to those who will benefit,” said Thomas Bock, M.D., CEO of Notable. “We hope that this agreement will also contribute and accelerate Oncoheroes’ mission”.

 “As a company solely committed to childhood cancer, we do not want to deviate our attention from developing new therapies for pediatric oncology. However, we are delighted about this out-licensing agreement as other patients can also benefit from our drug candidates,” said Ricardo Garcia, Oncoheroes’ co-founder and CEO. “Notable’s predictive precision medicine approach can revolutionize the traditional clinical development process and we are excited that volasertib will be one of their first assets to be assessed”.

Photo: Ricardo Garcia, Oncoheroes’ co-founder and CEO.